In navigating toward payment reform, where are we going, and what’s the motive for getting there?
Financial Risk Management in Health Care
Assuming business risk is part of the new healthcare marketplace. Healthcare risk management requires new approaches and insights and forward-looking thinking in rapidly changing circumstances. What is your risk management plan?
Article by Timothy Crowley
It’s a generally accepted view that all hospital-employed physician groups are constitutionally incapable of operating without financial support from the hospital. PinnacleHealth Medical Group found that commonsense tactics can eliminate the need for hospitals to expend precious resources to support employed physicians.
Article by Michael Rosenblatt & Henri Termeer
We can’t afford for current trends to continue. There is only one solution.
Navigating Pharmaceutical Price Increases: A Strategy to Protect Appropriate Use, Reduce Waste, and Identify Therapeutic Alternatives
Case Study by Umesh Khot, Michael Militello & Eric Vogan
In the face of major pharmaceutical price increases, Cleveland Clinic developed a strategy to ensure high-quality patient care while maintaining financial stability.
Article by Hannah Alphs Jackson, James Giblin & Michael Abecassis
Federal pay-for-performance models offer two paths to achieving value. The ultimate goal: rewarding the habit of performance excellence rather than one-time or random acts of performance improvement.
What is the necessity of moving toward more payer or provider risk in the Medicaid space?
Article by Henry Aaron, Matthew Fiedler, Paul B. Ginsburg, Loren Adler & Alice M. Rivlin
The threat to individual market stability is real. We need to fix it before it's too late.
Infographic by NEJM Catalyst
The loss of CSR payments would create some short term chaos in the market, but it would not significantly impact the number of people covered.
Article by Mark R. Depman
Will applying the RCA rubric to hospital admissions better help define and manage care?
Article by Jeremy A. Greene & William V. Padula
Why, in the early 21st century, are so many drugs that were cheaply available in the 20th century becoming prohibitively expensive?